The ex vivo manipulation of cells central to current approaches to cancer vaccines imposes a large economic and regulatory burden, dendritic cell modifications may be dependent on culture conditions and transient, and the vast majority of transplanted cells die following transplantation, leading to weak immune responses. The long-term objective is to bypass ex vivo cell manipulation in breast cancer vaccines, and instead develop effective material systems that program the immune ...
Reports by Author
